Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Probi AB (publ)
  6. News
  7. Summary
    PROB   SE0001280355

PROBI AB (PUBL)

(PROB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Probi publ : and Írebro University to collaborate on research into exploration of novel, needle free vaccines

07/02/2020 | 04:01am EDT

Örebro University, in collaboration with Probi AB, and nine other Swedish companies have been granted funding for research into novel, needle free vaccines through delivery via mucous membranes instead of using traditional injections.

Researchers will develop different types of novel vaccines and investigate vaccination through the mucous membranes. The delivery technology project will include the use of probiotic bacteria as carriers for the vaccine antigens, with the aim of inducing immunity against pathogens. The capability of probiotic bacteria to persist in close proximity to the mucosal surfaces will be utilized for presenting the vaccine antigens to the immune system and exerting immune-stimulating effects.

"This type of vaccine already exists today, for instance for polio. However, in general, vaccination via the mucous membranes are underused, even though many virus and bacteria enter the body this way", says Magnus Johansson, professor in bio-medicine and project manager of the research project.

"A lot of virus and bacteria enter the body through the mucous membranes, where a majority of our immune system is located. Therefore, we believe that probiotics can play a vital role as delivery carrier", Professor Magnus Johansson explains.

Titti Niskanen, Director R&D & Clinical Operations at Probi, adds: "We are proud to be working with Örebro University and the other parties in order to examine how to meet a clear unmet medical need. Being part of a vaccine technology development which can actually help save lives is very special to Probi, as this was the reason for Probi's foundation almost 30 years ago."

"Industry-academic partnerships are powerful engines to drive innovation, and we hope that the research project will result in a new vaccine delivery technology that can be used in the fight of any future virus pandemic, like the Covid-19 which we are currently experiencing", Professor Magnus Johansson concludes.

 

FOR FURTHER INFORMATION, CONTACT:

Titti Niskanen, Director R&D & Clinical Operations, Probi, tel +46 46 286 89 68, e-mail: titti.niskanen@probi.com
Tom Rönnlund, CEO, Probi, tel +46 46 286 89 40, e-mail: trd@probi.com

 

ABOUT PROBI

Probi is a world leader within probiotics. Our vision is to help people live healthier lives by delivering effective and well-documented probiotics, with proven health benefits based on scientific research. Probi offers dedicated probiotic expertise and partnership all the way from R&D to finished products for companies within the consumer healthcare and food industry. Our GMP certified manufacturing facilities produce probiotics in custom made formats with value-adding delivery technologies. Founded by scientists in Sweden 1991, Probi is a multinational company with 4 centers of excellence, active in more than 40 markets around the world and holding over 400 patents worldwide. Read more at www.probi.com

The 10 companies participating in "utvecklavaccin@oru":

Valneva Sweden AB
Eurocine Vaccines AB
Adlego Biomedical AB
Svenska Vaccinfabriken Produktion AB
Mivac Development AB
Nordic BioAnalysis AB
Probi AB
Academy of Quality in Pharm Science AB
GU Ventures AB
Vecura (Karolinska universitetssjukhuset)

https://news.cision.com/probi/r/probi-and-orebro-university-to-collaborate-on-research-into-exploration-of-novel--needle-free-vaccin,c3147162

https://mb.cision.com/Main/1556/3147162/1273520.pdf

(c) 2020 Cision. All rights reserved., source Press Releases - English

Stocks mentioned in the article
ChangeLast1st jan.
PROBI AB (PUBL) 10.08% 546 Delayed Quote.17.54%
SYMRISE AG -0.09% 112.25 Delayed Quote.3.69%
All news about PROBI AB (PUBL)
04:06aPROBIá : and Oriflame enter partnership for digestive...
PU
04:01aPROBIá : and Oriflame enter partnership for digestive probiotic concept launch
AQ
05/31PROBIá : Improved probiotic products for women's health - an unmet market need
AQ
05/31PROBIá : Change in the number of shares and votes in Probi
AQ
05/31PROBIá : Improved probiotic products for women's health – an unmet...
PU
05/10PROBI AB (PUBL) : Ex-dividend day for final dividend
FA
05/07PROBIá : Annual General Meeting 2021
AQ
04/23Q1 2021 : Good growth in the first quarter
AQ
04/22PROBIá : and China National Pharmaceutical Foreign Trade Corporation have signed..
AQ
04/21PROBIá : Iron status in healthy pregnant women improved by the probiotic Probi F..
AQ
More news
Financials
Sales 2021 758 M 91,2 M 91,2 M
Net income 2021 119 M 14,3 M 14,3 M
Net cash 2021 318 M 38,3 M 38,3 M
P/E ratio 2021 47,6x
Yield 2021 0,32%
Capitalization 5 651 M 679 M 680 M
EV / Sales 2021 7,04x
EV / Sales 2022 6,11x
Nbr of Employees -
Free-Float 36,5%
Chart PROBI AB (PUBL)
Duration : Period :
Probi AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PROBI AB (PUBL)
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
 
Mean consensus -
Number of Analysts 2
Average target price 505,00 SEK
Last Close Price 496,00 SEK
Spread / Highest target 1,81%
Spread / Average Target 1,81%
Spread / Lowest Target 1,81%
EPS Revisions
Managers and Directors
NameTitle
Tom Juhani R÷nnlund Chief Executive Officer
Henrik Lundkvist Chief Financial Officer
Jean-Yves Parisot Chairman
Niklas Brandt Vice President-Information Technology
Niklas Larsson Lead Scientific Affairs
Sector and Competitors
1st jan.Capitalization (M$)
PROBI AB (PUBL)17.54%679
NESTLÉ S.A.9.17%356 540
MONDELEZ INTERNATIONAL, INC.9.10%91 393
YIHAI KERRY ARAWANA HOLDINGS CO., LTD-15.28%77 762
THE KRAFT HEINZ COMPANY23.54%52 375
DANONE10.64%46 938